Clinical course of recurrent respiratory papillomatosis: Comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11

Gi, Robin E. A. Tjon Pian; Giorgi, Michel R. M. San; Slagter‐Menkema, Lorian; Hemel, Bettien M. van; Laan, Bernard F. A. M. van der; Heuvel, Edwin R. van den; Dikkers, Frederik G.; Schuuring, Ed

doi:10.1002/hed.23808

Cited by 58 publications

(61 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…uman papillomavirus 11 (HPV11), which belongs to species 10 of the Alphapapillomavirus genus (Alpha-PV), is etiologically associated with approximately 20% of anogenital warts and 30 to 40% of laryngeal papillomas (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). HPV11 is generally considered a low-risk HPV type due to its rare presence in HPVrelated cancers in humans, especially cervical cancer (9).…”

mentioning

confidence: 99%

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences

Jelen

Chen

Kocjan

et al. 2016

J Virol

View full text Add to dashboard Cite

Human papillomavirus 11 (HPV11) is an etiological agent of anogenital warts and laryngeal papillomas and is included in the 4-valent and 9-valent prophylactic HPV vaccines. We established the largest collection of globally circulating HPV11 isolates to date and examined the genomic diversity of 433 isolates and 78 complete genomes (CGs) from six continents. The genomic variation within the 2,800-bp E5a-E5b-L1-upstream regulatory region was initially studied in 181/207 (87.4%) HPV11 isolates collected for this study. Of these, the CGs of 30 HPV11 variants containing unique single nucleotide polymorphisms (SNPs), indels (insertions or deletions), or amino acid changes were fully sequenced. A maximum likelihood tree based on the global alignment of 78 HPV11 CGs (30 CGs from our study and 48 CGs from GenBank) revealed two HPV11 lineages (lineages A and B) and four sublineages (sublineages A1, A2, A3, and A4). HPV11 (sub)lineage-specific SNPs within the CG were identified, as well as the 208-bp representative region for CG-based phylogenetic clustering within the partial E2 open reading frame and noncoding region 2. Globally, sublineage A2 was the most prevalent, followed by sublineages A1, A3, and A4 and lineage B. IMPORTANCEThis collaborative international study defined the global heterogeneity of HPV11 and established the largest collection of globally circulating HPV11 genomic variants to date. Thirty novel complete HPV11 genomes were determined and submitted to the available sequence repositories. Global phylogenetic analysis revealed two HPV11 variant lineages and four sublineages. The HPV11 (sub)lineage-specific SNPs and the representative region identified within the partial genomic region E2/noncoding region 2 (NCR2) will enable the simpler identification and comparison of HPV11 variants worldwide. This study provides an important knowledge base for HPV11 for future studies in HPV epidemiology, evolution, pathogenicity, prevention, and molecular assay development. Human papillomavirus 11 (HPV11), which belongs to species 10 of the Alphapapillomavirus genus (Alpha-PV), is etiologically associated with approximately 20% of anogenital warts and 30 to 40% of laryngeal papillomas (1-11). HPV11 is generally considered a low-risk HPV type due to its rare presence in HPVrelated cancers in humans, especially cervical cancer (9). HPV11 is present in 0.5% of samples from HPV-positive women with a normal cytology worldwide and causes 2.3% of cervical low-grade squamous cell intraepithelial lesions (12, 13). However, rare case reports of HPV11-positive cases of cervical and anal squamous cell carcinomas, malignantly transformed laryngeal papillomas, and sinonasal inverted papillomas associated with squamous cell carcinoma can be found in the literature (14-21). Due to its clinical significance, HPV11 has been included in the current quadrivalent and nonavalent prophylactic HPV vaccines (22,23).The genetic diversity of HPV11 was studied for the first time in 1995, when Heinzel et al. sequenced the noncoding upstre...

show abstract

mentioning

confidence: 99%

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences

Jelen

Chen

Kocjan

et al. 2016

J Virol

View full text Add to dashboard Cite

show abstract

“…Furthermore the natural decreasing surgical rate of RRP was not taken into account [6, 22]. It is unknown if there is a immune response after vaccination which explains a clinical response, therefore this study was conducted.…”

Section: Discussionmentioning

confidence: 99%

“…HPV typing was performed using the HPV consensus primer set GP5+/6+ with subsequent nucleotide sequence analysis. Details of this technique have been described before [6]. …”

Section: Methodsmentioning

confidence: 99%

“…It is associated with HPV6 and 11 for 80–100 % of cases [6–10]. Therapy focuses on repeated surgical removal of exophytic lesions.…”

Section: Introductionmentioning

confidence: 99%

“…Therapy focuses on repeated surgical removal of exophytic lesions. Some patients may need over a 100 surgical interventions to keep the airway open and the voice sufficient [6]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis

Giorgi

Pawlita

et al. 2016

Eur Arch Otorhinolaryngol

Self Cite

View full text Add to dashboard Cite

Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil®) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (p < 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.

show abstract

Evaluation of Safety of Intralesional Cidofovir for Adjuvant Treatment of Recurrent Respiratory Papillomatosis

Hoesli

Thatcher

Hogikyan

et al. 2020

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

ecurrent respiratory papillomatosis (RRP) is a disease characterized by benign papillomatous lesions of the upper airway that often cause debilitating dysphonia and may result in airway obstruction. Because of its recurrent nature, multiple surgical excisions are required to manage RRP, resulting in patient morbidity and high health care use. 1,2 Intralesional injections of the antiviral medication cidofovir have been used in an attempt to decrease the frequency of excisions and reduce the burden of disease for the patient 3,4 ; however, there have been concerns that cidofovir may produce adverse effects, including increased risk of malignant transformation. 5 Although several studies have found no increased risk of cancer in patients with RRP who are treated with cidofovir, [6][7][8][9][10][11] the safety profile of intralesional cidofovir injection in patients with RRP is not fully understood. Understanding the safety of intralesional cidofovir is essential for otolaryngologists treating patients with RRP with a high burden of disease who may be seeking adjuvant therapies. This study aims to provide further data on the safety of intralesional adjuvant cidofovir to inform physicians in their decision to offer this treatment to patients.Recurrent respiratory papillomatosis results from human papillomavirus infection, most commonly with subtypes 6 and 11. 12,13 Human papillomavirus is thought to infect the stem cells within the basal layer of the epithelium and either cause active disease or remain dormant. 14 The lesions of RRP IMPORTANCE The use of intralesional cidofovir injections for recurrent respiratory papillomatosis (RRP) remains controversial owing to concern regarding the risks of its use, including increased risk of dysplasia or carcinogenesis.OBJECTIVE To describe the rates of dysplasia, development of malignant lesions, and adverse events associated with use of intralesional cidofovir injections as adjuvant treatment for RRP compared with patients treated without adjuvant cidofovir. DESIGN, SETTING, AND PARTICIPANTSIn this case series performed at a tertiary care referral center, review of electronic medical records on all adult and pediatric patients (N = 154) treated for RRP with adequate follow-up from January 1, 2000, to December 31, 2016, was performed. Data were collected on the use of cidofovir, development and presence of dysplasia or malignant lesions, complications, and intersurgical interval.EXPOSURES Adjuvant intralesional cidofovir or surgical excision only. MAIN OUTCOMES AND MEASURESThe main outcomes measured were the development of dysplasia, malignant lesions, and complications from treatment. These outcomes were determined before collection of data. RESULTSOf the 154 patients included in the analysis, 83 patients (53.9%) received adjuvant intralesional cidofovir and 71 patients (46.1%) underwent surgical excision only. One hundred patients (64.9%) were male; mean age was 27.7 (95% CI, 24.3-31.2) years. Patients were followed up for a median (interquartile range) of 70 (24-118) mont...

show abstract

Clinical course of recurrent respiratory papillomatosis: Comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11

Abstract: Anatomically, HPV11-associated RRP behaves more aggressively. Younger patients with HPV11 and older patients with HPV6 experience a worse clinical course of RRP.

Cited by 58 publications

References 37 publications

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences

Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis

Evaluation of Safety of Intralesional Cidofovir for Adjuvant Treatment of Recurrent Respiratory Papillomatosis

Contact Info

Product

Resources

About